Targeting of NMDA receptors in new treatments for schizophrenia
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Abnormalities in glutamatergic neurotransmission mediated by N-methyl-d-aspartate (NMDA) are implicated in the pathophysiology of schizophrenia, although the precise mechanisms are unknown. AREAS COVERED: The author examines the role of the NMDA receptor in schizophrenia, focusing on results from preclinical and clinical studies that support the NMDA receptor hypothesis of schizophrenia. The author first reviewed papers detailing alterations in the levels of endogenous substances such as glutamine, glutamate, d-serine, l-serine, kynurenic acid and glutathione (GSH), all of which can affect NMDA receptor function. Next, the author reviewed clinical findings for glycine, d-serine, d-cycloserine, d-amino acid oxidase inhibitors (e.g., sodium benzoate) and glycine transporter-1 inhibitors (e.g., sarcosine, bitopertin), as potential therapeutic drugs. In addition, the author outlined how oxidative stress associated with decreased levels of the endogenous antioxidant GSH may play a role in the pathophysiology of schizophrenia. Finally, the author reviewed N-acetylcysteine (NAC), a precursor of GSH and an activator of the cystine-glutamate antiporter, as a potential therapeutic drug. EXPERT OPINION: Given the NMDA receptor hypothesis of schizophrenia, the glycine modulatory site on NMDA receptors is the most attractive therapeutic target for this disease. In addition, both the kynurenine pathway and cystine-glutamate antiporter represent credible potential therapeutic targets for schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glutamate Receptor Ion Channels: Structure, Regulation, and Function
Traynelis, S. F., Wollmuth, L. P., McBain, C. J., Menniti, F. S., Vance, K. M., Ogden, K. K., Hansen, K. B., Yuan, H., Myers, S. J., & Dingledine, R. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002451 · Cited by 3,568 · cited 1×
“The NMDA receptor is composed of four subunits: two obligatory GluN1 subunits and a combination of two GluN2 subunits (GluN2A, GluN2B, GluN2C and GluN2D) and/or GluN3 subunits (GluN3A and GluN3B) [2].”
BackgroundKrystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Metabolism and functions of glutathione in brain
Dringen, R. (2000) · Progress in Neurobiology · doi:10.1016/s0301-0082(99)00060-x · Cited by 1,702
Glutamate receptor dysfunction and schizophrenia
Olney, J. W. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240016004 · Cited by 1,685 · cited 1×
“Multiple lines of evidence suggest that dysfunctional glutamatergic neurotransmission via the NMDA receptor could underlie the pathophysiology of schizophrenia [3-11].”
BackgroundKynurenines in the mammalian brain: when physiology meets pathology
Schwarcz, R., Bruno, J. P., Muchowski, P. J., & Wu, H.-Q. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3257 · Cited by 1,530
Moghaddam, B., & Javitt, D. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.181 · Cited by 1,035
Amminger, G. P., Schäfer, M. R., Papageorgiou, K., Klier, C. M., Cotton, S. M., Harrigan, S. M., Mackinnon, A., McGorry, P. D., & Berger, G. E. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.192 · Cited by 896
Cognitive Functioning in Prodromal Psychosis: A Meta-analysis
Fusar-Poli, P., Deste, G., Smieskova, R., Barlati, S., Yung, A. R., Howes, O., Stieglitz, R.-D., Vita, A., McGuire, P., & Borgwardt, S. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.1592 · Cited by 691 · cited 1×
“A recent meta-analysis showed that adolescents and young adults at high-risk for developing psychosis demonstrated cognitive impairment before the onset of psychosis [144].”
BackgroundThe Glutamatergic Dysfunction Hypothesis for Schizophrenia
Coyle, J. T. (1996) · Harvard Review of Psychiatry · doi:10.3109/10673229609017192 · Cited by 568 · cited 1×
“Multiple lines of evidence suggest that dysfunctional glutamatergic neurotransmission via the NMDA receptor could underlie the pathophysiology of schizophrenia [3-11].”
Background
Cited by
Zhang, J.-C., Yao, W., & Hashimoto, K. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666160119094646 · Cited by 538
“In addition, KA is a known endogenous antagonist at α7 nicotinic acetylcholine receptors (nAChR) which are implicated in the pathophysiology of neuropsychiatric disorders [73-79].”
Self-citationGlutamate hypothesis in schizophrenia
Uno, Y., & Coyle, J. T. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12823 · Cited by 367
Early interventions in risk groups for schizophrenia: what are we waiting for?
Sommer, I. E., Bearden, C. E., van Dellen, E., Breetvelt, E. J., Duijff, S. N., Maijer, K., van Amelsvoort, T., de Haan, L., Gur, R. E., Arango, C., et al. (2016) · npj Schizophrenia · doi:10.1038/npjschz.2016.3 · Cited by 140
Essential Role of Keap1-Nrf2 Signaling in Mood Disorders: Overview and Future Perspective
Hashimoto, K. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01182 · Cited by 98
“These findings suggest that dietary-intake of glucoraphanin-rich vegetables in high-risk psychosis subjects might prevent the transition to psychosis in young adulthood (Hashimoto, 2014; Shirai et al., 2015; Matsuura et al., 2018).”
BackgroundHashimoto, K., Bruno, D., Nierenberg, J., Marmar, C. R., Zetterberg, H., Blennow, K., & Pomara, N. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.8 · Cited by 90
Self-citation
Metadata
- Authors
- Hashimoto, K.
- Venue
- Expert Opinion on Therapeutic Targets
- Publisher
- Informa Healthcare
- Published
- 2014-06-26
- Volume
- 18
- Issue
- 9
- Pages
- 1049-1063
- ISSN
- 1472-8222 (ISSN-L)
- 1744-7631
- OpenAlex
- W2110011082
- Cited by
- 115
- References
- 29
- FWCI
- 13.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting of NMDA receptors in new treatments for schizophrenia. https://app.cochat.ai/papers/10.1517/14728222.2014.934225
- The paper
- Hashimoto, K. (2014). Targeting of NMDA receptors in new treatments for schizophrenia. Expert Opinion on Therapeutic Targets. https://doi.org/10.1517/14728222.2014.934225
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.